Institutional members access full text with Ovid®

Share this article on:

A RANDOMIZED CONTROLLED TRIAL OF PANRETINAL PHOTOCOAGULATION WITH AND WITHOUT INTRAVITREAL RANIBIZUMAB IN TREATMENT-NAIVE EYES WITH NON–HIGH-RISK PROLIFERATIVE DIABETIC RETINOPATHY

Ferraz, Daniel A. MD*,†; Vasquez, Lisa M. MD*; Preti, Rony C. MD, PhD*; Motta, Augusto MD*; Sophie, Raafay MD; Bittencourt, Millena G. MD; Sepah, Yasir J. MBBS; Monteiro, MÁrio L. R. MD, PhD*; Nguyen, Quan dong MD, MSc; Takahashi, Walter yukihiko MD, PhD*

doi: 10.1097/IAE.0000000000000363
Original Study

Purpose: To compare the efficacy of panretinal photocoagulation (PRP) and intravitreal ranibizumab injection with PRP alone in patients with treatment-naive bilateral non–high-risk proliferative diabetic retinopathy.

Methods: Sixty eyes of 30 patients were randomized either to the study group (SG) receiving PRP plus 2 ranibizumab injections or to the control group (CG) receiving PRP alone. Mean change in best-corrected visual acuity and in optical coherence tomography were compared at baseline and 1, 3, and 6 months.

Results: Best-corrected visual acuity was significantly better at 6 months in the SG; however, there was decrease in best-corrected visual acuity in the CG. Central macula thickness decreased significantly at 6 months in SG when compared with baseline (−47.6 μm, P < 0.001) and did not reveal significant difference in the CG. In eyes with diabetic macular edema, best-corrected visual acuity increased by 3.6 letters (P = 0.06) in the SG and decreased by 4.4 letters in the CG (P = 0.003). Central macula thickness decreased by 69.3 μm (P = 0.001) in the SG and decreased by 45.5 μm (P = 0.11) in the CG.

Conclusion: Intravitreal ranibizumab in combination with PRP can be an effective treatment in eyes with non–high-risk proliferative diabetic retinopathy and diabetic macular edema.

Intravitreal ranibizumab in combination with PRP can be an effective treatment in eyes with non–high-risk proliferative diabetic retinopathy and diabetic macular edema.

*Division of Ophthalmology, University of São Paulo, São Paulo Medical School, São Paulo, Brazil;

Ocular Imaging Research and Reading Center, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska; and

Retinal Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.

Reprint requests: Walter Yukihiko Takahashi, MD, PhD, University of São Paulo, Av. São Gualter, 99, São Paulo, SP 05455-000 Brazil; e-mail: wytakahashi@uol.com.br

Q. D. Nguyen serves on the Scientific Advisory Board for various studies sponsored by Genentech, and chairs the steering committee for the RISE/RIDE studies. The authors have no financial/conflicting interests to disclose.

Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01746563.

© 2015 by Ophthalmic Communications Society, Inc.